James Edward Ackroyd

James Edward Ackroyd is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of cancer treatment through his innovative patents. With a total of two patents to his name, Ackroyd's work focuses on developing antibodies that target specific cancer-related proteins.

Latest Patents

Ackroyd's latest patents include groundbreaking inventions such as CRTAM antibodies and methods of treating cancer. This patent discloses antibodies directed against CRTAM, along with nucleic acids encoding these antibodies. The methods outlined in this patent aim to treat various human cancers, including small cell lung cancer, non-small cell lung cancer, melanoma, breast cancer, and many others. His second patent involves conjugated antibodies against LY75 for the treatment of cancer. This invention provides antibodies that bind to LY75, along with nucleic acid molecules encoding these antibodies and methods for their expression. These antibodies are intended for the treatment of several types of cancer, including pancreatic, ovarian, breast, and lung cancer.

Career Highlights

James Edward Ackroyd is currently associated with Oxford Biotherapeutics Ltd, where he continues to advance his research in cancer therapies. His work has the potential to significantly impact the treatment landscape for various malignancies.

Collaborations

Ackroyd collaborates with talented individuals in his field, including Arnima Bisht and Rachel L Dusek. Their combined expertise contributes to the innovative research and development efforts at Oxford Biotherapeutics Ltd.

Conclusion

James Edward Ackroyd's contributions to cancer treatment through his innovative patents highlight his role as a significant inventor in the field. His work continues to pave the way for new therapeutic options for patients battling cancer.

This text is generated by artificial intelligence and may not be accurate.